Vincristine Resistance in Rat Intestinal Tumors
Author Information
Author(s): P. Incel, Karen J. Finney, D.R. Appleton, J.P. Sunter, A.J. Watson
Primary Institution: University of Newcastle upon Tyne
Hypothesis
The study investigates vincristine resistance in primary intestinal tumors induced by dimethylhydrazine in rats.
Conclusion
The study found that primary intestinal tumors are more resistant to vincristine than normal mucosa.
Supporting Evidence
- An increase in resistance to vincristine was shown over normal mucosa.
- The fitted lines show an enhanced vincristine dose requirement over normal mucosa of 6 times in colonic tumors and 8 times in small intestinal tumors.
- Non-neoplastic mucosa from DMH-treated animals requires an enhanced dose of vincristine of 1.5 times compared with normal mucosa.
Takeaway
The researchers looked at how well a cancer drug works on tumors in rats, finding that the tumors needed much more of the drug to be affected compared to normal tissue.
Methodology
The study involved treating rats with dimethylhydrazine to induce tumors and then measuring the resistance to vincristine using the Post-Metaphase Index.
Limitations
The study did not ascertain tissue concentrations of vincristine, which may affect the interpretation of results.
Participant Demographics
Ninety-eight male Wistar rats were used in the study.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.001
Want to read the original?
Access the complete publication on the publisher's website